Collaboration on Microbiome Research
In an exciting development for microbiome science, Sequential Skin Ltd, a leader in skin microbiome testing, has partnered with AMILI, renowned for its expertise in gut microbiome research. Together, they will embark on a significant project backed by a $1.8 million grant aimed at enriching the understanding of how the gut and skin microbiomes interact. This innovative initiative promises to advance our knowledge of inflammatory skin disorders (ISDs) such as atopic dermatitis and psoriasis.
Understanding the Microbiome Connection
Chronic inflammatory skin disorders affect a sizable percentage of the global population, with studies indicating that 20-25% of people experience these conditions at some point in their lives. The impact of ISDs extends beyond physical symptoms to encompass emotional and psychological implications as well. Research highlights the pivotal role of the skin microbiome in mitigating disease processes, while imbalances within the gut microbiota can exacerbate skin issues. Previous methods of microbiome analysis heavily focused on the skin alone, missing crucial insights that a more integrative approach could provide.
Sequential's Leadership in Skin Microbiome Testing
With a robust database housing over 25,000 clinical skin microbiome samples, Sequential Skin has positioned itself at the forefront of this field. Since the launch of its early skin microbiome at-home tests in 2019, the company has continued to innovate, collaborating with more than 80 personal care and pharmaceutical companies worldwide. This collaborative research will build on Sequential's established capabilities and contribute to more effective interventions.
AMILI's Contributions to Gut Microbiome Knowledge
Headquartered in Singapore, AMILI has been instrumental in developing comprehensive studies of the gut microbiome. Notably, its founders performed the first gut microbiome transplants in the region back in 2014. AMILI has created Asia's most extensive multi-ethnic gut microbiome database, aiming to understand the connections between gut microbiome changes and various health conditions. The synergy with Sequential promises to accelerate the discovery of accurate diagnostics and treatments focusing on the gut-skin axis.
Exciting Future Prospects
Both organizations are optimistic about the potential advancements this partnership will bring to microbiome-driven interventions. Dr. Oliver Worsley, CEO of Sequential, expressed enthusiasm about this competitive grant's success, stating how it could pioneer novel approaches to characterize inflammatory skin conditions more effectively. Similarly, Dr. Jeremy Lim, CEO of AMILI, highlighted the importance of this collaboration in enhancing diagnostic testing for ISDs, emphasizing the necessity of integrating gut-skin microbiome knowledge.
Frequently Asked Questions
What is the main goal of the Sequential and AMILI collaboration?
The collaboration aims to investigate the connection between the gut and skin microbiomes to improve understanding and treatment of inflammatory skin disorders.
How will the $1.8 million grant be utilized?
The grant will fund research that develops targeted, microbiome-driven interventions focusing on inflammatory skin conditions.
What role does Sequential Skin play in this project?
Sequential Skin leads in skin microbiome testing, providing extensive databases and pioneering at-home tests.
Why is the gut-skin axis important?
The gut-skin axis is crucial because imbalances in gut microbiota can significantly impact skin health, making integrated studies vital.
What outcomes are expected from this research?
The expected outcomes include more effective diagnostics and non-invasive treatment options for ISDs, enhancing patient care and understanding of the microbiomes.
